About this trial
Chronological aging significantly contributes to structural and functional alterations in the vasculature, making it a major risk factor for atherosclerotic disease and its acute thrombotic events. DNA damage, including telomeric, non-telomeric, and mitochondrial damage, is recognized as a key initiator of vascular aging and atherogenesis. There is abundant evidence indicating the presence of oxidative DNA lesions, telomere erosion, and mitochondrial DNA damage in both experimental and human plaques, as well as in the peripheral cells of atherosclerotic patients.
It is increasingly evident that genomic instability activates signaling pathways that lead to a multitude of pathophysiological cellular and molecular changes. These changes promote inflammation, apoptosis, autophagy, and ultimately, cellular senescence, accompanied by the "senescence-associated secretory phenotype" (SASP). However, the precise mechanisms linking the DNA damage response (DDR) to senescence, SASP in vascular cells, and the pathogenesis of atherosclerosis and vulnerable atheroma are yet to be fully understood. Additional research is needed to delineate the underlying mechanisms through which mitochondrial dysfunction influences telomere length and vice versa, and how their interaction contributes to the vascular aging process. Progress in this area has the potential to uncover therapeutic targets and novel, more precise diagnostic, and prognostic indicators.
The objectives of the VICTORIA study are to examine the levels of aging-related non-coding RNA deregulation (specifically lncRNA TERRA and mitomiR) and peripheral markers of cell aging (including telomere length and mitochondrial DNA content) across the various spectra of angina pectoris (stable angina, unstable angina, NSTEMI, and STEMI). Additionally, the study aims to determine whether these markers are correlated with vulnerable plaque characteristics and major adverse cardiovascular events.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with acute coronary syndromes (unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI))
stable angina
non-angiographically significant coronary diseases recovered for elective diagnostic or interventional procedures
Disqualifiers
cardiac shock
congestive heart failure
end stage renal diseases
coronary artery bypass graft
Trial population
Patients with acute or chronic coronary syndromes
Trial design
Cohort
Prospective
Treatments tested in this trial
Several biomarkers
Other interventionTelomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
Treatment groups
Trial outcomes
Primary outcomes
Telomere length
Telomere length (LTL) is an index of genetic instability and senescence. LTL is measured in the DNA (extracted from blood leucocytes) by RT-PCR. Measure unit: 2\^(-ddct) or kilobases
Secondary outcomes
Mitochondrial DNA copy number (mtDNAcn)
Indices of mitochondrial deregulation Measure unit: 2\^(-ddct) or kilobases
MitomiR
Indices of mitochondrial deregulation
Long non-coding (lnc) RNA TERRA
modulator of telomerase
pro-oxidant cytokines
expression of SASP phenotype. - picograms/ml
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Niguarda Hospital
Lead sponsor
Istituto di Fisiologia Clinica CNR
Collaborator